Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a ...

Fintel reports that on May 28, 2025, Stifel downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from Buy to Hold.

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

On Tuesday, Stifel analysts downgraded Vigil Neuroscience Inc (NASDAQ: VIGL) stock from a Buy to a Hold rating, concurrently reducing the price target from $11.00 to $8.00. This adjustment comes ...

Sanofi SAN0.69%increase; green up pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL 0.13%increase; green up pointing triangle for approximately $470 million ...

Expected closure in Q3 2025. Vigil Neuroscience, Inc. has announced a definitive merger agreement with Sanofi, under which Vigil's shareholders will receive up to $10.00 per share in cash ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...